Authors: Martha Powell, Future Science Group
In light of our recent World Immunization Week interview with John-Arne Røttingen founding Chief Executive Officer for the Coalition for Epidemic Preparedness Innovations (CEPI), we take a closer look at the three emerging viruses CEPI has prioritized for vaccine development – Middle East Respiratory Syndrome (MERS), Nipah and Lassa.
MERS, Nipah and Lassa fever have all been identified as the initial targets of a sizeable investment from CEPI, which aims to boost vaccine development and subsequently prevent future epidemics.
In our recent interview, Røttingen discussed CEPI’s role in epidemic preparedness and the method by which these pathogens were chosen as investment priorities. Here, we focus on the known facts about these diseases, the impact they have had on populations thus far and why medical countermeasures against them are so urgently required.